1. Value in Health Regional Issues
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective 
Katherine A. Vilain, MPH, Ming Chin Yang, DrPH, Elise Chia Hui Tan, PhD, Kaijun Wang, PhD, Haiyan Li, MS, Wan Hsuan Hsu, MSc, Robert P. Giugliano, David J. Cohen, Elizabeth A. Magnuson, ScD 
Value in Health Regional Issues 
Volume 12, Pages (May 2017)
DOI: /j.vhri
Copyright © Terms and Conditions

2. Fig. 1
Representation of the decision model. M represents a Markov process with 20 total health states [9 alive states, each on or off treatment, and 2 absorbing (death) states]. Cycle length is 3 months. Patients remain in their current health state unless a worse event occurs, with the probabilities of these events contingent upon the treatment option and whether patient is currently on or off treatment. Only one event may occur per cycle. The branch from Well represents the potential events, and other health states have branches with similar structures (not shown). CRNM – clinically relevant non-major, EDO – edoxaban, ECH - extracranial hemorrhage, ICH - intracranial hemorrhage, IS - ischemic stroke, MI - myocardial infarction, SEE - systemic embolic event, S/P - status post, TIA - transient ischemic event.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions

3. Fig. 2
Joint distribution of cost and effectiveness differences from probabilistic sensitivity analysis: edoxaban vs. warfarin.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions

4. Fig. 3
Cost-effectiveness acceptability curve, base case results for the comparison of edoxaban to warfarin, from probabilistic sensitivity analysis.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions

5. Fig. 4
1-way sensitivity analysis (tornado diagram) on ICER, edoxaban vs. warfarin.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions

6. Fig. 5
CHADS2 2-3 and CHADS2 4-6 subgroups: Cost-effectiveness acceptability curves from probabilistic sensitivity analyses.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions

7. Fig. 6
VKA-naïve and VKA-experienced strata: Cost-effectiveness acceptability curves from probabilistic sensitivity analyses.
Value in Health Regional Issues  , 74-83DOI: ( /j.vhri )
Copyright © Terms and Conditions